Abstract
Background: Patients with solitary metastasis of renal cell carcinoma (RCC) have shown to be ideal candidates for surgical metastasectomy (SM). However, whether SM will show more benefit than systemic therapy remains unclear. Methods: We included 73 patients treated for solitary metastasis after nephrectomy at our institute from April 2008 to December 2018. We compared the clinical outcomes between the SM (n = 29) and no-SM (n = 44) group which were treated with only systemic therapy. Results: Eleven of 29 patients in the SM group received presurgical targeted therapy (PTT). Although 13 of 29 patients in the SM group showed recurrence during the study period, a Cox proportional hazards model showed that SM was significantly associated with a favorable overall survival (hazard ratio: 0.18; p = 0.007). Patients receiving PTT prior to SM showed a longer recurrence-free survival after SM in comparison to those who underwent SM without PTT (median: not reached vs. 27.7 months; p = 0.009). Conclusions: If resection is feasible, SM may be beneficial for patients with solitary metastasis of RCC, and we showed the possibility that PTT prior to SM may be effective for avoiding recurrence after SM. Further large-scale prospective studies are needed to clarify the ideal treatment strategy for metastatic RCC.
References
1.
Motzer
RJ
, Jonasch
E
, Michaelson
MD
, Nandagopal
L
, Gore
JL
, George
S
, NCCN guidelines insights: kidney cancer, version 2.2020
. J Natl Compr Canc Netw
. 2019
;17
:1278
–85
. .2.
Ouzaid
I
, Capitanio
U
, Staehler
M
, Wood
CG
, Leibovich
BC
, Ljungberg
B
, Surgical metastasectomy in renal cell carcinoma: a systematic review
. Eur Urol Oncol
. 2019
;2
:141
–9
. .3.
Jakubowski
CD
, Vertosick
EA
, Untch
BR
, Sjoberg
D
, Wei
E
, Palmer
FL
, Complete metastasectomy for renal cell carcinoma: comparison of five solid organ sites
. J Surg Oncol
. 2016
;114
:375
–9
. .4.
Lyon
TD
, Thompson
RH
, Shah
PH
, Lohse
CM
, Boorjian
SA
, Costello
BA
, Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era
. J Urol
. 2020
;203
:275
–82
. .5.
Takagi
T
, Fukuda
H
, Ishihara
H
, Yoshida
K
, Kondo
T
, Kobayashi
H
, Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era
. Urol Oncol
. 2020
;38
:515
–20
. .6.
Sobin
LH
, Compton
CC
. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer
. Cancer
. 2010
;116
:5336
–9
. .7.
Heng
DY
, Xie
W
, Regan
MM
, Harshman
LC
, Bjarnason
GA
, Vaishampayan
UN
, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
. Lancet Oncol
. 2013
;14
:141
–8
. .8.
Kanda
Y
. Investigation of the freely available easy-to-use software “EZR” for medical statistics
. Bone Marrow Transplant
. 2013
;48
:452
–8
. .9.
Calvo
E
, Schmidinger
M
, Heng
DY
, Grünwald
V
, Escudier
B
. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
. Cancer Treat Rev
. 2016
;50
:109
–17
. .10.
Bögemann
M
, Zagorska
A
, Akumo
D
, Hadad
LE
, Pignot
M
. Using data from a sickness fund claims database to assess the treatment patterns and healthcare resource utilization among patients with metastatic renal cell carcinoma in Germany
. Urol Int
. 2020
;104
:982
–93
. .11.
Psutka
SP
, Master
VA
. Role of metastasis-directed treatment in kidney cancer
. Cancer
. 2018
;124
:3641
–55
. .12.
Shinohara
N
, Abe
T
. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma
. Int J Urol
. 2015
;22
:888
–97
. .13.
Procházková
K
, Vodička
J
, Fichtl
J
, Krákorová
G
, Šebek
J
, Roušarová
M
, Outcomes for patients after resection of pulmonary metastases from clear cell renal cell carcinoma: 18 years of experience
. Urol Int
. 2019
;103
:297
–302
. .14.
Meyer
CP
, Sun
M
, Karam
JA
, Leow
JJ
, de Velasco
G
, Pal
SK
, Complications after metastasectomy for renal cell carcinoma: a population-based assessment
. Eur Urol
. 2017
;72
:171
–4
. .15.
Yoshiyama
A
, Morii
T
, Susa
M
, Morioka
H
, Kobayashi
E
, Asano
N
, Preoperative evaluation of renal cell carcinoma patients with bone metastases on risks for blood loss, performance status and lethal event
. J Orthop Sci
. 2017
;22
:924
–30
. .16.
Tornberg
SV
, Visapää
H
, Kilpeläinen
TP
, Taari
K
, Järvinen
R
, Erkkilä
K
, Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era
. Scand J Urol
. 2018
;52
:419
–26
. .17.
Karam
JA
, Rini
BI
, Varella
L
, Garcia
JA
, Dreicer
R
, Choueiri
TK
, Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma
. J Urol
. 2011
;185
:439
–44
. .18.
Hughes
T
, Broucek
J
, Iodice
G
, Bommareddy
PK
, Basu
S
, Kaufman
HL
. Metastasectomy following incomplete response to high-dose interleukin-2
. J Surg Oncol
. 2018
;117
:572
–8
. .19.
Brehmer
B
, Kauffmann
C
, Blank
C
, Heidenreich
A
, Bex
A
. Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome
. World J Urol
. 2016
;34
:1061
–6
. .20.
Sternberg
CN
, Motzer
RJ
, Hutson
TE
, Choueiri
TK
, Kollmannsberger
C
, Bjarnason
GA
, COMPARZ post hoc Analysis: characterizing pazopanib responders with advanced renal cell carcinoma
. Clin Genitourin Cancer
. 2019
;17
:425
–35e4
. .21.
Motzer
RJ
, Tannir
NM
, McDermott
DF
, Arén Frontera
O
, Melichar
B
, Choueiri
TK
, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
. N Engl J Med
. 2018
;378
:1277
–90
. .22.
Rini
BI
, Plimack
ER
, Stus
V
, Gafanov
R
, Hawkins
R
, Nosov
D
, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
. N Engl J Med
. 2019
;380
:1116
–27
. .23.
Motzer
RJ
, Penkov
K
, Haanen
J
, Rini
B
, Albiges
L
, Campbell
MT
, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
. N Engl J Med
. 2019
;380
:1103
–15
. .24.
Larkin
J
, Minor
D
, D’Angelo
S
, Neyns
B
, Smylie
M
, Miller
WH
Jr, Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, apen-label phase III trial
. J Clin Oncol
. 2018
;36
:383
–90
. .25.
McDermott
DF
, Drake
CG
, Sznol
M
, Choueiri
TK
, Powderly
JD
, Smith
DC
, Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab
. J Clin Oncol
. 2015
;33
:2013
–20
. .26.
Horn
L
, Spigel
DR
, Vokes
EE
, Holgado
E
, Ready
N
, Steins
M
, Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)
. J Clin Oncol
. 2017
;35
:3924
–33
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
